摘要
嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)是通过基因工程技术将自体或异体T细胞改造成针对肿瘤特异性抗原的新型杀伤细胞,具有特异性强、效率高、非MHC限制等优点,在复发/难治性血液系统肿瘤和部分实体瘤中取得了良好的治疗效果。CAR-T细胞制备流程包括细胞分离和纯化、活化和分化、基因修饰、体外扩增、表型质控、保存和回输。近年来,随着流式细胞术的迅速发展,使其广泛应用于CAR-T细胞治疗的各个环节,包括治疗前筛查、体外制备和回输后监测,并在其创新优化过程中发挥着重要的作用。
Chimetic antigen receptor T cells(CAR-T)are a kind of novel killer cells derived from autogenous or allogeneic T cells targeting the tumor specific antigens by gene engineering transpormation.The CAR-T cells possess the advantages of high specificity,high efficiency and non-MHC restriction,thus achieving good therapeutic effects in relapsed/refractory hematological tumors and some solid tumors.The process of CAR-T cell preparation includes cell isolation and purification,activation and differentiation,gene modification,in vitro amplification,phenotypic quality control,preservation and reinfusion.In recent years,with the rapid development of flow cytometry,this technology has been widely used in all aspects of CAR-T cell therapy,including pre-treatment screening,in vitro preparation and posttransfusion monitoring,which plays an important role in its innovative optimization.
作者
李成功
梅恒
胡豫
LI Cheng-Gong;MEI Heng;HU Yu(Department of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology;The Cell Therapy Clinical Medical Center of Cancer Diseases of Hubei Province.Wuhan 430020,Hubei Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2020年第1期329-332,共4页
Journal of Experimental Hematology
基金
国家自然科学基金(81570116、81770132、81873434).
